Cited by 56Mast cells and histamineGastrointestinal Tumor Research and TreatmentHistiocytic Disorders and Treatments

Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis

Open access
Zanotti, Roberta, Bonifacio, Massimiliano, Lucchini, Giuseppe, Sperr, Wolfgang R., Scaffidi, Luigi, van Anrooij, Björn, Oude Elberink, Hanneke NC, Rossignol, Julien +40 more·2022·Leukemia

Abstract

In the current classification of the World Health Organization (WHO), bone marrow mastocytosis (BMM) is a provisional variant of indolent systemic mastocytosis (ISM) defined by bone marrow involvement and absence of skin lesions. However, no additional diagnostic criteria for BMM have been proposed. Within the registry dataset of the European Competence Network on Mastocytosis, we compared characteristics and outcomes of 390 patients with BMM and 1175 patients with typical ISM. BMM patients were significantly older, predominantly male, had lower tryptase and lower burden of neoplastic mast cells, and displayed a higher frequency of allergic reactions, mainly triggered by Hymenoptera, than patients with typical ISM. The estimated 10-year progression-free survival of BMM and typical ISM was 95.9% and 92.6%, respectively. In BMM patients defined by WHO-based criteria, the presence of one B-Finding and tryptase level ≥125 ng/mL were identified as risk factors for progression in multivariate analyses. BMM patients without any of these risk factors were found to have better progression-free survival (p < 0.05) and better overall survival (p < 0.05) than other ISM patients. These data support the proposal to define BMM as a separate SM variant characterized by SM criteria, absence of skin lesions, absence of B-Findings, and tryptase levels <125 ng/mL.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41375-021-01406-y

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. Horny HP, Akin C, Metcalfe DD, Swerdlow SH, Campo E, Harris NL, et al. World Health Organization (WHO) classification of tumours. Mastocytosis (Mast Cell Disease). Pathology & genetics. Tumours of haematopoietic and lymphoid tis- sues, vol. 2. Lyon, France: IARC Press; 2008. p. 54-63.
  2. Muñoz-González JI, Álvarez-Twose I, Jara-Acevedo M, Zanotti R, Perkins C, Jawhar M, et al. Proposed global prognostication score for systemic mastocytosis. Lancet Hematol 2021;8:e194-e204.

Cited by

Sorted by citations

Authors
Zanotti, R., Bonifacio, M., Lucchini, G., Sperr, W. R., Scaffidi, L., van Anrooij, B., Oude Elberink, H. N., Rossignol, J., Hermine, O., Gorska, A., Lange, M., Hadzijusufovic, E., Miething, C., Müller, S., Perkins, C., Shomali, W., Elena, C., Illerhaus, A., Jawhar, M., Parente, R., Caroppo, F., Solomianyi, O., Zink, A., Mattsson, M., Yavuz, A. S., Panse, J., Varkonyi, J., Doubek, M., Sabato, V., Breynaert, C., Vucinic, V., Schug, T., Hägglund, H., Wortmann, F., Brockow, K., Angelova-Fischer, I., Belloni Fortina, A., Triggiani, M., Reiter, A., Hartmann, K., Malcovati, L., Gotlib, J., Shoumariyeh, K., Niedoszytko, M., Arock, M., Kluin-Nelemans, H. C., Bonadonna, P., & Valent, P.
Affiliations
  • University of Verona (IT)
  • Ludwig Boltzmann Institute for Hematology and Oncology (AT)
  • Centre National de la Recherche Scientifique (FR)
  • Gdańsk Medical University (PL)
  • University of Veterinary Medicine Vienna (AT)
  • University of Freiburg (DE)
  • Stanford Medicine (US)
  • Policlinico San Matteo Fondazione (IT)
  • University of Cologne (DE)
  • Heidelberg University (DE)
  • University of Salerno (IT)
  • University of Padua (IT)
  • Johannes Kepler University of Linz (AT)
  • Technical University of Munich (DE)
  • Uppsala University (SE)
  • Istanbul University (TR)
  • Universitätsklinikum Aachen (DE)
  • Masaryk University (CZ)
  • University of Antwerp (BE)
  • Universitair Ziekenhuis Leuven (BE)
  • University of Graz (AT)
  • University of Lübeck (DE)
  • University of Basel (CH)
  • University of Pavia (IT)
  • Pitié-Salpêtrière Hospital (FR)
  • Azienda Ospedaliera Universitaria Integrata Verona (IT)
Corresponding author
Bonifacio, Massimiliano
Venue
Leukemia
Published
2021-09-20
Volume
36
Issue
2
Pages
516-524
ISSN
  • 0887-6924 (ISSN-L)
  • 1476-5551
OpenAlex
W3201033674
Cited by
56
References
38
Citations by year
2026: 4 · 2025: 8 · 2024: 13 · 2023: 12 · 2022: 14 · 2021: 4
FWCI
4.01
Type
journal article
Language
en
Open access
Locations
  • Leukemia (publishedVersion)
  • PubMed (publishedVersion)
  • Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, other-oa)
  • Lirias (KU Leuven) (submittedVersion)
  • mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
  • RWTH Publications (RWTH Aachen) (submittedVersion)
  • Padua Research Archive (University of Padova) (submittedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
Funders
Università degli Studi di Verona
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Mast cells and histamine
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal Tumor Research and Treatment
  • Health Sciences › Medicine › Physiology › Histiocytic Disorders and Treatments
Keywords
bone marrow mastocytosis, indolent systemic mastocytosis, diagnostic criteria, tryptase, progression-free survival, overall survival, risk factors for progression, allergic reactions, hymenoptera venom allergy
MeSH terms
Adult, Aged, Aged, 80 and over, Bone Marrow, Europe, Female, Follow-Up Studies, Humans, Male, Mast Cells, Mastocytosis, Middle Aged, Prognosis, Skin Diseases, Survival Rate, Mastocytosis, Systemic, Tryptases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review